Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Krystal Biotech (KRYS) Share Price
Media headlines about Krystal Biotech (NASDAQ:KRYS) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Krystal Biotech earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.599406330406 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Reviewing Krystal Biotech (KRYS) and Its Peers (americanbankingnews.com)
- Zacks: Krystal Biotech Inc (KRYS) Receives Consensus Rating of “Strong Buy” from Analysts (americanbankingnews.com)
- Krystal Bio’s KB105 an Orphan Drug for rare skin disorder (seekingalpha.com)
- Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis (finance.yahoo.com)
- Financial Analysis: Krystal Biotech (KRYS) vs. Its Peers (americanbankingnews.com)
Shares of NASDAQ:KRYS remained flat at $$16.01 during mid-day trading on Friday. The company had a trading volume of 18,612 shares, compared to its average volume of 38,724. The stock has a market capitalization of $165.77 million and a P/E ratio of -10.82. Krystal Biotech has a 12 month low of $8.03 and a 12 month high of $19.25.
Several brokerages have recently commented on KRYS. LADENBURG THALM/SH SH set a $38.00 price objective on Krystal Biotech and gave the company a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Krystal Biotech in a research report on Monday, August 6th. William Blair assumed coverage on Krystal Biotech in a research report on Monday, August 6th. They issued a “buy” rating on the stock. Finally, ValuEngine upgraded Krystal Biotech from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $30.33.
In other Krystal Biotech news, COO Suma Krishnan bought 25,000 shares of the business’s stock in a transaction dated Wednesday, June 6th. The shares were purchased at an average price of $11.02 per share, with a total value of $275,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Antony A. Riley bought 2,800 shares of the business’s stock in a transaction dated Tuesday, May 22nd. The shares were acquired at an average cost of $10.75 per share, for a total transaction of $30,100.00. The disclosure for this purchase can be found here. Insiders own 45.80% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Article: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.